ArticleThe American journal of psychiatry2026
Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample.
Article in The American journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveSubstance use disorders (SUDs) are associated with risk of psychiatric comorbidities, with inconsistent sex differences across studies. The objective of this study was to determine odds of psychiatric comorbidities based on sex in persons with a primary diagnosis of opioid, alcohol, or cannabis dependence, using a national clinical dataset.
methodsThis was a cross-sectional study of data from state-funded and state-run mental health programs in 2022 (Mental Health Client-Level Data, from the U.S. Substance Abuse and Mental Health Services Administration). Data were obtained from adults (age ≥18 years) with a primary diagnosis of either opioid (N=28,808), alcohol (N=23,281), or cannabis dependence (N=5,961). Data from individuals with each SUD were examined for psychiatric comorbidity outcomes, based on secondary diagnoses of an anxiety disorder, bipolar disorder, a depressive disorder, schizophrenia or other psychotic disorder, or a trauma- and stressor-related disorder versus no comorbidity. Data were analyzed with multinomial logistic regressions, examining sex, race, ethnicity, and age as predictors.
resultsMales with a primary diagnosis of opioid, alcohol, or cannabis dependence had lower adjusted odds of anxiety, bipolar, depressive, and trauma- and stressor-related disorders compared to females. However, males with opioid or cannabis dependence had higher adjusted odds of schizophrenia or other psychotic disorders compared to females. Adjusted analyses also detected associations of race and ethnicity with specific comorbidities.
conclusionsIn this recent national clinical dataset, sex-based differences were observed in specific psychiatric comorbidities for each of these three SUDs. Future studies should examine biopsychosocial mechanisms that underlie these differences, with the goal of improving personalized care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.